Delivery of brain-derived neurotrophic factor via nose-to-brain pathway

Pharmaceutical Research

Volumn 29, Issue 2, 2012, Pages 441-447

  Vaka, Siva Ram Kiran ^a   Murthy, Sathyanarayana Narasimha ^a,c   Balaji, Anna ^b   Repka, Michael A ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b Vaageswari Institute of Pharmaceutical Sciences   (India)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

BDNF; Chitosan; Nose brain; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CHITOSAN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG TRANSPORT; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILIZATION STRESS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OLFACTORY EPITHELIUM; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; VISCOSITY; ANIMAL; BIOAVAILABILITY; BRAIN; CHEMISTRY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHITOSAN; DRUG CARRIERS; MALE; OLFACTORY MUCOSA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84860854802     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0572-9     Document Type: Article

References (45)

1. Thorne RG, Frey 2nd WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet. 2001;40:907-46. (Pubitemid 34066688)
2. Dawbarn D, Allen SJ. Neurotrophins and neurodegeneration. Neuropathol Appl Neurobiol. 2003;29:211-30. (Pubitemid 36718170)
3. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glialderived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999;46:419-24. (Pubitemid 29416283)
4. Schulte-Herbruggen O, Braun A, Rochlitzer S, Jockers-Scherubl MC, Hellweg R. Neurotrophic factors-a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? Curr Med Chem. 2007;14:2318-29. (Pubitemid 47618040)
5. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 2001;63:71-124.
6. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677-736. (Pubitemid 32695243)
7. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors. 2004;22:123-31. (Pubitemid 39377904)
8. Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev. 2008;59:201-20.
9. Phillips HS, Hains JM, Laramee GR, Rosenthal A, Winslow JW. Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science. 1990;250:290-4.
10. Wetmore C, Ernfors P, Persson H, Olson L. Localization of brainderived neurotrophic factor mRNA to neurons in the brain by in situ hybridization. Exp Neurol. 1990;109:141-52. (Pubitemid 20256208)
11. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J. 1990;9:2459-64.
12. Lu B, Gottschalk W. Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Prog Brain Res. 2000;128:231-41. (Pubitemid 35461239)
13. Frodl T, Schule C, Schmitt G, Born C, Baghai T, Zill P, et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry. 2007;64:410-16. (Pubitemid 46556460)
14. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol. 2008;210:154-63.
15. Yulug B, Ozan E, Gonul AS, Kilic E. Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Res Bull. 2009;78:267-69.
16. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15:1768-77.
17. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant like effect of brain derived neurotrophic factor (BDNF). Pharmacol Biochem Behav. 1997;56:131-7.
18. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22:3251-61. (Pubitemid 35379212)
19. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 2008;1211:37-43.
20. Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat. 2009;5:433-49.
21. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9:589-95. (Pubitemid 36597106)
22. Deierborg T, Soulet D, Roybon L, Hall V, Brundin P. Emerging restorative treatments for Parkinson's disease. Prog Neurobiol. 2008;85:407-32.
23. Thoenen H, Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci. 2002;5:1046-50. (Pubitemid 35247196)
24. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5:311-22.
25. Burke MA, Mobley WC, Cho J, Wiegand SJ, Lindsay RM, Mufson EJ, et al. Loss of developing cholinergic basal forebrain neurons following excitotoxic lesions of the hippocampus: rescue by neurotrophins. Exp Neurol. 1994;130:178-95.
26. Sakane T, Pardridge WM. Carboxyl-directed pegylation of brainderived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res. 1997;14:1085-91. (Pubitemid 27371411)
27. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Rev. 1998;27:1-39. (Pubitemid 28300281)
28. Frey W, Liu J, Chen X, Thorne R, Fawcett J, Ala T, et al. Delivery of 125 I-NGF to the brain via the olfactory route. Drug Deliv. 1997;4:87-92. (Pubitemid 27276124)
29. Hanson LR, Frey 2nd WH. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol. 2007;2:81-6.
30. Vaka SRK, Sammeta SM, Day LB, Murthy SN. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci. 2009;98:3640-46.
31. Schmidt MC, Simmen D, Hilbe M, Boderke P, Ditzinger G, Sandow J, et al. Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium. J Pharm Sci. 2000;89:396-407. (Pubitemid 30152439)
32. Tengamnuay P, Sahamethapat A, Sailasuta A, Mitra AK. Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts. Int J Pharm. 2000;197:53-67. (Pubitemid 30125777)
33. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci. 2001;14:201-7. (Pubitemid 32884316)
34. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003;87:187-98. (Pubitemid 36255456)
35. Jadhav K, Gambhire M, Shaikh I, Kadam V, Pisal S. Nasal Drug Delivery System-Factors Affecting and Applications. Current Drug Therapy. 2007;2:27-38. (Pubitemid 46723136)
36. Zhang Y, Zhang Q, Sun Y, Sun J, Wang X, Chen M. Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies. Bio Pharm Bull. 2005;28:2263-7. (Pubitemid 41757417)
37. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res. 1992;9:1-9.
38. Yamamoto A, Hayakawa E, Lee VH. Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implication in peptide delivery from nonoral routes. Life Sci. 1990;47:2465-74.
39. Alcala-Barraza SR, Lee MS, Hanson LR, McDonald AA, Frey 2nd WH, McLoon LK. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target. 2010;18:179-90.
40. Deckner ML, Frisen J, Verge VM, Hokfelt T, Risling M. Localization of neurotrophin receptors in olfactory epithelium and bulb. Neuroreport. 1993;5:301-4. (Pubitemid 24026259)
41. Porsolt RD, LePichon M, Jalfre M. Depression; a new animal model sensitive to antidepressant treatments. Nature. 1977;266:730-31.
42. Sutanto W, de Kloet ER. The use of various animal models in the study of stress and stress related phenomena. Lab Anim. 1994;28:293-306. (Pubitemid 24311824)
43. Duman R, Malberg J, Nakagawa S, Disa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry. 2000;48:732-9.
44. McEween B. Effects of adverse experiences for brain structure and function. Biol Psychiatry. 2000;48:721-31.
45. Sapolsky R. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry. 2000;48:755-65.